Orders Grew 14%, the Guide Grew 5%, and One Backlog Disclosure Explains Why

Results vs. Consensus

This was the cleanest quarter of our coverage period. In February the demand indicators were excellent and the printed P&L went nowhere. In May the top line missed and margins carried the quarter. In August revenue and cash finally caught up with the order book. In this quarter all four elements moved together: volume, price, margin and earnings. The only soft line is cash, and that softness is small, specific and visible.

Against the company's own August guidance

Consensus is the weaker test here. Emerson gave quarter-specific guidance for sales, group growth, margin and both EPS measures in August, so the quarter can be graded line by line against what management committed to.

Year-over-year comparison

Every figure below traces to the income statement, cash flow statement and segment tables in the results release. Growth rates are computed on the levels shown in the same row.

Sequential comparison

Full-year FY26 versus FY25

Two presentation points on the full year. First, the four quarterly adjusted EPS figures ($1.46, $1.54, $1.71, $1.86) sum to $6.57, while the results release reports $6.59 for the year. The $0.02 gap is quarterly rounding, and the full-year figure governs. Second, management describes FY26 as a sixth consecutive year of double-digit adjusted EPS growth. On the reported levels the increase is 9.7%, which rounds to the 10% the company cites. The streak depends on that rounding.

Revenue assessment. The seven-point underlying increase splits four points volume and three points price, with currency neutral. That is the best mix of the year and a material change from Q2's half-point of underlying growth on negative volume. Importantly, the strength was not concentrated: Software & Systems grew 14% underlying, Intelligent Devices 4% and Safety & Productivity 2%, and each exceeded its own guide. Geographically all three reported regions grew, with the Americas up 9%, Asia / Middle East / Africa up 7% and even Europe positive at 1%. We have not seen all three regions positive in any other quarter of this coverage period. The qualification is that Final Control's 5% came partly from Middle East project shipments that had been deferred out of earlier quarters, so some of this is timing recovered rather than demand created.

Margin assessment. The 29.1% adjusted segment EBITA margin is the highest of the four FY26 quarters, ahead of 27.7% in Q1, 27.6% in Q2 and 28.5% in Q3, and 160 basis points above the comparable quarter. It is also 90 basis points above the full-year figure, which is the shape management needs if the 30% target for 2028 is to be reached from a 28.2% FY26 base. The composition deserves scrutiny, though. Management attributed the beat largely to one segment: Control Systems & Software printed 33.1% against 27.0% a year earlier, helped by five points of price in the segment, favourable project close-outs and an easy comparison against the weakest quarter of FY25. Those are real but not all repeatable. Gross margin rose a more modest 78 basis points to 52.7%, and 61 basis points of operating leverage came from SG&A discipline rather than the factory.

EPS assessment. Management's bridge is tight and we can reconcile it. The $0.24 adjusted increase comprises $0.25 from operations, of which $0.19 came from Software & Systems, against a $0.01 currency headwind. Beneath that, a $45M corporate cost overrun cost roughly $0.05 and was offset by lower interest, a smaller share count and a year-over-year tax benefit. So the adjusted beat is operational and the below-the-line items roughly cancelled. The GAAP line is where the quarter disappoints. GAAP EPS of $1.33 came in $0.12 below the ~$1.45 guided, because add-backs totalled $0.53 against the $0.40 the guide implied. Restructuring alone contributed $0.14 of add-back in the quarter.

Segment Performance

The five reported segments sit inside three business groups. Software & Systems combines Control Systems & Software with Test & Measurement; Intelligent Devices combines Sensors with Final Control. The group rows are subtotals, and both the sales and the adjusted EBITA columns foot to the company totals.

Control Systems & Software

The quarter's engine, and the segment that explains most of the margin beat. Sales grew 14% underlying after 7% in Q3 and a 2% decline in Q2, and adjusted EBITA rose from $298M to $412M. The 610-basis-point margin expansion is the largest single-segment margin move in the portfolio this quarter, and management was unusually specific about why, including the uncomfortable parts.

"Q4 had several tailwinds. We continue to do very well in power. So Ovation is in that segment and continues to do well. We had a good quarter in software, so the mix was good. It was the end of the year where we have got project closeouts that typically happen. Sometimes those are a positive. Sometimes they are a negative this year; they were positives. And then we also had good price there. We had the pricing dynamic with the memory cost coming in. I think we talked about it before that in Q3, we had a little bit of leakage in price that all came back in Q4. So they had 5 points of price in that segment." — Michael Baughman, Chief Financial Officer

Ovation orders grew 26%, and management separately sized the control-systems portion of the power business as up close to 45%, driven primarily by greenfield work. Against the prior year's 27.0% margin, which management called the lowest quarter of FY25, the comparison was the easiest available.

Assessment: This is a strong segment having an exceptionally favourable quarter, and the honest reading is that both are true. Five points of segment price including recovered Q3 leakage, positive project close-outs and the year's easiest comparison will not all repeat. We carry the demand strength into FY27 and explicitly do not carry 33.1%, which is why our FY27 incremental assumption sits below the 51% the quarter realised.

Test & Measurement

The National Instruments business delivered the outcome the acquisition case required. Underlying sales grew 15%, orders grew 14% with semiconductor orders up 59%, and adjusted margin reached 30.3%. The more important number is annual: the segment's full-year adjusted EBITA margin reached 29.0% against 25.3% in FY25, and GAAP segment earnings turned positive for the full year at $47M against a $68M loss, despite absorbing $429M of annual intangible amortisation.

"Our commitment there was to get to 31% in 5 years. We ended the year at 29%. I certainly would expect there to be a point-plus of improvement coming. Or going through 2027. So certainly on track with the commitments that we laid out at the beginning there." — Michael Baughman, Chief Financial Officer

Management is planning FY27 deliberately conservatively here: high single-digit growth with a strong first half and a moderating second half, on an explicit assumption that the semiconductor cycle cools. Automotive, now under $200M of the portfolio, is the only slow end market in the segment.

Assessment: Bull 3 is confirmed on the strongest evidence yet. A full fiscal year of positive GAAP segment earnings removes the argument that the integration's operating gains could never reach reported profit. The cyclical qualification stands, and management has placed it in the plan rather than leaving it for the market to discover. That is the right posture, and it is also where FY27 upside sits if the cycle holds.

Sensors

Underlying growth of 3% after 7% in Q3, with adjusted margin easing 30 basis points to 30.0%. On a full-year basis, though, the segment's margin improved to 29.3% from 28.6%, which clears the bar management set in February when it guided to some improvement on the FY25 base after a weak Q1.

Assessment: The February concern that a second soft quarter would reclassify Sensors from a mix problem to a demand problem has been answered across the year rather than in any one quarter. We treat this as a stable 30%-margin business growing with its installed base, not a source of acceleration.

Final Control

Sales grew 5% underlying, the segment's best quarter of the year, with margin flat at 27.2%. Management credited project shipments in the Middle East that had been held back by export constraints. The full-year margin reached 26.8% against 26.2%, but the cost of getting there is visible: full-year restructuring and related costs in this segment were $93M against $30M in FY25, more than triple, and $17M of that landed in Q4.

Assessment: The segment supports the conversion case and complicates the margin case, exactly as it did last quarter. Flat margin on 5% growth, with greenfield mix diluting price, is a reminder that the funnel's duration comes at a cost. The tripled restructuring spend still has no published savings bridge, so we give it no permanent margin credit.

Safety & Productivity

Growth of 2% underlying with margin up 30 basis points to 22.9%, on North American electrical and utility strength against persistent European weakness. The full-year margin of 21.7% improved from 21.5%, while GAAP segment earnings fell to $416M from $418M on $27M of restructuring against $10M.

Assessment: Unchanged from last quarter. This is the portfolio's slowest and lowest-margin business, and its FY27 guide of 3% to 4% sits above the 2% underlying growth it delivered in FY26. It supports the plan without changing the multiple the portfolio deserves.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management was the most confident of the four calls in this coverage period, and the confidence was carried by delivered results rather than by framework language. The notable shift is that it answered pointed questions with the unflattering detail and sized each item rather than deflecting: the corporate cost overrun, the non-repeating components of the best segment's margin, and the fall in near-term backlog convertibility all came out in Q&A, with numbers attached. Where it was least convincing was on the free cash flow shortfall, which went unaddressed in the prepared remarks and unasked in Q&A.

1. The order print is real, and the guide is not inconsistent with it

Underlying orders grew 14% with every business group and every region contributing, led by Software & Systems at 18% and Intelligent Devices at 13%. Backlog reached $8.2B, up 11%, on a 1.01 book-to-bill that management described as above typical seasonality. The first question on the call asked the obvious thing: why does a 14% order print and 11% backlog growth produce only a ~5% revenue guide? Management answered with Europe and China caution. The better answer came later in the call, in response to a different question.

"You will see in the 10-K, you know, we make that disclosure of the percent of the backlog in the next 12 months. And that has been pretty sticky at 75% for a long time. That dropped to 70%." — Michael Baughman, Chief Financial Officer

That reconciles the guide arithmetically. Backlog of $8.2B at 70% convertibility gives roughly $5.74B shipping within twelve months. A year earlier, $8.2B less 11% growth gives about $7.39B at 75%, or roughly $5.54B. The near-term convertible backlog therefore grew in the low single digits, around 3% to 4%, while total backlog grew 11%. Both figures are rounded, so the derived growth rate carries a band of roughly 2% to 5%, but the conclusion holds across the whole band: the portion of the order book that can become FY27 revenue grew far more slowly than the headline.

Assessment: This is the most useful disclosure of the quarter and it cuts both ways. It vindicates the guide as realistic rather than sandbagged, which removes one of the easier bull arguments. It also confirms the duration case: Emerson is trading near-term convertibility for multi-year visibility, which is the right trade for a business whose terminal value depends on the capex cycle lasting. Bull 2 stays ON TRACK, with the qualification now explicit and quantified rather than assumed.

2. The FY27 guide meets consensus and front-loads nothing

Management guided FY27 to ~5% reported and underlying sales growth, a 29% adjusted segment EBITA margin, adjusted EPS of ~$7.25 and free cash flow of $3.8B to $3.9B. The Street was at approximately $7.26 before the print, so this is an in-line guide, not a raise. GAAP EPS is guided to ~$5.70, with ~$1.41 of intangible amortisation and ~$0.14 of restructuring bridging to the adjusted figure.

The earnings phasing is notably even. The Q1 adjusted EPS midpoint of $1.60 is 9.6% above Q1 FY26's $1.46, and the implied Q2-to-Q4 balance of $5.65 is 10.1% above the comparable $5.13. After a back-loaded FY26 plan, that symmetry matters: this guide does not require a second-half inflection to work. Margin is the exception, with Q1 guided to ~28% against a ~29% year, which management attributed to project mix, first-half start-up costs for a capacity expansion reading through Intelligent Devices, and continued investment.

Assessment: The shape of this guide is the most reassuring thing about it. Bear 2, established in February on the premise that the FY26 plan was back-loaded, does not have an FY27 equivalent on earnings. Our own bridge, holding the FY26 adjusted tax rate of 21.5% and assuming the share count falls toward 551M on the announced repurchases, lands modestly above $7.25 at about $7.36. The guide therefore does not lean on an aggressive tax or share-count assumption, which is why we are comfortable estimating slightly above it.

3. Close to half of the FY27 margin expansion is the software renewal reversal

The software contract renewal dynamic has shaped every quarter of this coverage. It cost $0.06 of adjusted EPS in Q1 and $0.09 in Q2, and management sized its full-year FY26 margin cost at 70 basis points. Asked where the reversal lands, management gave the number.

"Obviously, this year, it was a bit of a headwind with the renewal dynamic costing us 70 basis points. As we have talked about that unwinds roughly half next year, half in 2028. We will get a little more than half next year. So for the year, that should be a tailwind of around 35 basis points." — Michael Baughman, Chief Financial Officer

That is 35 of the 80 basis points of guided FY27 margin expansion, or 44% of it, arriving as the mechanical reversal of a prior-year accounting drag rather than as operating leverage. Running the arithmetic: 29% on roughly $19.93B of FY27 revenue gives $5,780M of adjusted segment EBITA, a $420M increase on $949M of incremental sales, or a 44% incremental margin. Remove the 35 basis points and the implied operating incremental falls to about 37%, below the 40% framework. The same logic extends further out. Reaching 30% in 2028 requires another 100 basis points, and management has placed roughly 35 of those in the second half of the renewal unwind.

Assessment: Bull 4 remains ON TRACK, because the target is being met and the quarterly evidence is good. But the operating content of the remaining path is thinner than the headline trajectory implies: across FY27 and FY28 together, roughly 70 of the 180 basis points needed are renewal accounting. We hold our incremental-margin assumption below the quarter's realised level for this reason, and we would treat a 2028 margin target hit largely on renewal reversal as a weaker outcome than the number alone suggests.

4. Free cash flow missed the company's own guide

FY26 free cash flow was $3,535M, up 8.9%, against the ~$3.6B management moved to in August. Operating cash flow of $3,978M came in below the ~$4.1B guided. Q4 free cash flow of $916M fell roughly $66M short of the ~$982M the August guide required. This is a small miss in percentage terms, about 1.8% on free cash flow, and it went unmentioned in the prepared remarks and unasked in Q&A.

It matters for two reasons. The first is continuity: cash has been the soft element of this story since February, and our May and August reports both carried a discount to the company's cash guidance. In August we estimated FY26 free cash flow at ~$3.55B with an implied Q4 of ~$0.93B against the company's ~$3.6B and ~$0.982B. The actuals were $3,535M and $916M. Our discount was correct and slightly too small.

The second reason is composition. The full-year operating cash flow increase of $302M decomposes awkwardly.

Working capital consumed $329M more cash than in FY25, and a $245M favourable swing in an undisclosed "Other, net" line covered about three-quarters of that shortfall. Without that swing, operating cash flow would have grown $57M, or 1.6%, and free cash flow would have been roughly $3.29B rather than $3,535M. Some of the swing is almost certainly the lapping of AspenTech transaction items and the IEEPA refunds, but the release does not disclose the composition, and it does not disclose how much refund cash was collected in the year as distinct from the $91M pretax income benefit.

Assessment: This is Bear 2's successor. The FY26 question of whether a back-loaded guide would be met is now answered: it was, on revenue, margin and adjusted EPS, and it was not on cash. The FY27 free cash flow guide of $3.8B to $3.9B implies a 19.1% to 19.6% margin against the 20% the 2028 framework requires, so the cash leg is the one place where the three-year plan is not comfortably ahead of itself. We apply a modest discount again and will treat the first two quarters of FY27 as the test.

5. GAAP earnings and a restructuring add-back that keeps growing

GAAP diluted EPS of $1.33 missed the ~$1.45 guide by $0.12, and FY26 GAAP EPS of $4.79 missed the ~$4.89 guide by $0.10, in a year when adjusted EPS beat by $0.04. The gap is entirely add-backs, and because Emerson guides each add-back line separately, the miss reconciles exactly.

Restructuring is the overwhelming cause. Management guided the Q4 restructuring add-back at approximately $0.03 and delivered $0.14, nearly five times the figure, and it did so after having already raised the full-year number twice during the year.

The FY26 restructuring add-back finished 50% above the figure guided one quarter earlier and more than double February's. At the dollar level, full-year restructuring and related costs were $227M against $162M in FY25, with Final Control's $93M against $30M the largest single driver. The FY27 guide of ~$0.14 asks the market to accept a 61% reduction from the FY26 actual, from a company that raised this number twice during FY26 and then exceeded the higher figure. The FY27 add-back bridge is also structurally narrower in another way: it contains lines only for amortisation and restructuring, implying no acquisition or divestiture fees, no discrete taxes and no pension mark-to-market, where FY26 actually carried $0.14, $0.05 and $(0.01) respectively.

Assessment: Adjusted EPS of $6.59 is a fair representation of FY26 operating earnings, and we value the company on it. But the $1.80 gap to GAAP is 27% of adjusted EPS, and a fifth of that gap is restructuring spending with no published savings bridge, which finished above guidance after two upward revisions. We treat the ~$0.14 FY27 restructuring assumption as the single most likely line in the guide to be revised higher, and we do not credit the implied GAAP EPS acceleration to ~$5.70 at face value.

6. Growth verticals carried the year, and acquired a new risk the day after the call

The growth verticals grew 21% in FY26 and now represent 27% of sales, roughly $5.1B. In Q4 they grew 25%, with LNG up 68% on project deliveries, semiconductor up 43% and power up 24%. Management separately sized the power business at about $2.5B growing 25%, without naming the period, and put the control-systems portion of it, which is primarily greenfield, up close to 45%. The project funnel rose $600M sequentially and 17% year over year to $13B, and quarterly funnel wins accelerated to approximately $575M from roughly $400M in Q3 and $450M in Q2, with 75% coming from the growth verticals. Named wins included a world-scale ethylene cracker complex in Qatar, LNG Canada's Phase 2 expansion doubling Kitimat capacity from 14 to 28 million tonnes per annum, and a ten-year DeltaV manufacturing-execution subscription with a life-sciences contract manufacturer. Management also expanded rather than consumed its LNG opportunity set: of 315 million tonnes per annum identified a year ago, roughly 100 were awarded in 2026, and the remaining opportunity is now put at 275.

FY27 assumes low double-digit growth from the verticals, with power and LNG at the high end, aerospace and defence high single to low double digit, life sciences high single digit and semiconductor deliberately modelled at mid single digit on a cautious second half.

Assessment: Bull 1 is confirmed on the evidence in front of us: the demand is booked, the funnel is growing, and the wins are named and dated. We are establishing a new bear point rather than weakening the bull, because the risk is to a policy environment rather than to Emerson's execution. It is not yet in any disclosed number, on either side, and we size it in our downside case rather than in the base.

7. Software clears the target that has been outstanding all year

Annual contract value grew 10.1% to $1.7B. That target, 10%-plus exiting FY26, was reaffirmed without a bridge at the February, May and August calls while ACV printed 9% three consecutive times. It has now been met. Separately, management declared the AspenTech integration complete, with $100M of synergies realised, two years ahead of its original schedule.

"We are very excited about the momentum that is building at Aspen. As we came through the second half of this year. The team delivering overall in software and systems 10% ACV growth and gives us confidence as we go into 2028." — Surendralal Lanca Karsanbhai, President and Chief Executive Officer

FY27 ACV is guided to approximately 10%, so the exit rate becomes the run rate rather than a step toward something higher. On the AI-enabled products, management described strong customer reception for the NI test assistant and clear migration toward the LabVIEW tier that contains it, but again supplied no quantified revenue contribution.

Assessment: The upgrade signpost we have carried since February is met, and it is the main reason our estimate moves above the company's guide rather than to it. Two qualifications keep it from doing more. Guiding FY27 ACV to approximately 10% means the software business is now a 10% grower rather than an accelerating one, and a completed integration removes a source of future synergy as well as a source of cost. We still attach no separate AI revenue premium.

8. Intelligent Devices remains capped by Europe and China

Intelligent Devices grew 4% underlying in Q4, above its ~3% guide, and 3% for the full year. FY27 is guided to 3% to 4% in Q1 and 4% for the year, inside a long-range framework management describes as 3% to 6%. Asked what would take the group back to the high single digits it has printed in better years, management was direct about the binding constraint.

"You know, for us, Europe and China, so I think impact of Europe and China in intelligent devices is significant and that really has to turn in a meaningful way. We have not. We do not see that. We do not see that where we are talking a high single digit." — Ram R. Krishnan, Chief Operating Officer

On China specifically, management quantified the structural problem: roughly 40% of its approximately $1B of China sales is exposed to petrochemical and refining, a market it describes as over-capacitised and not forming new capital. Test & Measurement grew 31% in China but is only about $200M of the total. China orders remain negative. Europe declined 1% in FY26 and is modelled at low single-digit growth in FY27, with Germany, France and Italy explicitly described as soft and no inflection expected.

Assessment: This is the honest ceiling on the story. Intelligent Devices is 55% of company sales and is planned to grow at 4%, which is why the company total is ~5% despite verticals at low double digits. The useful detail is that management is not forecasting a recovery it cannot see, so neither Europe nor China is a source of guidance risk in FY27. Both are instead unbanked upside, which is a materially better position than the one Bear 3 described in May.

9. Pricing normalises, and price-cost stays positive

FY26 carried approximately 3% price, of which a point was tariff-related recovery and two points were normalised pricing. FY27 assumes 2%.

"Going into next year, we feel pretty good about 2% price in the plan. Normal level of pricing. I think it is supported by our positioning in almost every category in every end market. So we feel pretty good. that is how we have gone into the year now. Certainly inflation, particularly material inflation, we have modeled in electronics, and some of the pricing related to memory will be unfavorable. Tariffs will be marginally favorable versus this year. But net, good positive green on price-cost should underwrite the incrementals and the margin plan for next year." — Surendralal Lanca Karsanbhai, President and Chief Executive Officer

Assessment: Reasonable and specific, including the named headwind. Memory and electronics inflation is a real cost for a business that puts semiconductors in instruments, and management has identified it rather than assumed it away. Two points of price on ~5% growth means roughly three points of volume in the FY27 plan, a point below what Q4 delivered. That is a sensible step down, not a stretch.

10. Capital allocation steps up sharply, and the buyback is front-loaded

Emerson raised the quarterly dividend 7% to $0.595 per share, payable December 10, and guided FY27 capital return to approximately $3.8B: $2.5B of repurchases and $1.3B of dividends. The repurchase figure is 2.5 times the $1.0B completed in FY26, and approximately $1.5B of it is planned for Q1 alone, more than the entire FY26 program in a single quarter. FY26's $1.0B retired 7.2 million shares, an implied average of about $139 per share against the $162.61 current price.

Management framed the front-loading as buying flexibility, and did not hide the valuation judgment inside it.

"So front loading gave us the opportunity to get the benefit of the lower share count that will, you know, support the 2027 guide. While giving us flexibility as the year unfolds, if an opportunity, a bolt on comes up, we can do that. And still be in a position to deliver 2028. So it was really buying us some flexibility." — Michael Baughman, Chief Financial Officer

On larger transactions, management was unambiguous that sub-billion-dollar bolt-ons remain live and that the large-scale acquisitions of the prior era are "not in the cards in this plan."

The three-year framework introduced in November 2025 largely stands up to the arithmetic. Cumulative capital return of $2.24B in FY26 plus ~$3.8B in FY27 reaches roughly $6.0B of the $10B commitment, leaving about $4.0B for FY28, split as $2.5B of repurchase against the $6B three-year buyback leg and roughly $1.46B of dividends against the $4B leg. The buyback leg is on pace, while the dividend leg needs about 12% more in FY28 than the ~$1.3B planned for FY27.

Assessment: This is the cleanest part of the story, and it is the strongest evidence for Bear 1 being contained. Net debt fell $1.20B across FY26 to $10.37B, gross debt fell 7.2% to $12.18B, and the company is nonetheless able to step the buyback up 2.5 times without new leverage. A $2.5B repurchase is 2.7% of the current market capitalisation, so the share-count tailwind to FY27 EPS is real and already in the guide. We note only that a buyback executed at $139 average last year is being accelerated at a price 17% higher.

11. Corporate costs broke badly, and part of the step-up persists

Adjusted corporate and other expense was $81M in the quarter against $34M a year earlier, and, asked about it in Q&A, management said it came in roughly $45M worse than planned. The explanation was itemised rather than waved away: foreign-exchange headwinds, an expected gain on non-operating assets that did not arrive alongside an impairment that did, and an unusually bad medical-claims experience. The full-year figure was $209M.

"All the goodness I talked about at CS&S, we have the exact opposite story at the corporate level, and we were about $45 million higher than we had expected to be. I would tell you that is several individually inconsequential items that all added up to a big number. And if you look at the EPS bridge, I think it is worth noting that was about $0.05 that was offset by lower interest and share count, and we continue to get tax benefits year over year." — Michael Baughman, Chief Financial Officer

Looking forward, management expects the $45M of one-offs largely not to repeat but is adding roughly $25M of incremental digital-enablement investment through FY27, covering commercial tools, contracting and human-resources systems, bridging to an FY27 corporate and other assumption of approximately $195M.

Assessment: The disclosure is a credit to management and the amount is immaterial to the thesis, but it is worth noting what it reveals about the quarter's shape. The adjusted EPS beat of $0.01 came with a $0.05 corporate miss inside it, offset below the line by interest, share count and tax. Both the operating result and the below-the-line offsets were better than modelled, and they happened to cancel. That is a stronger operating quarter than the headline surprise, and a less clean one.

12. The Middle East headwind shrank faster than management expected

The conflict cost Emerson approximately $85M of FY26 revenue, against the ~$100M estimated in August and the ~$150M estimated in May. In Q4 Middle East and Africa sales grew 19% and Middle East orders rose 42%, and management attributed a smaller-than-expected revenue impact to customers and field teams finding ways to maintain continuity as the disruption extended. FY27 models the Middle East up high single digits, explicitly conditional on no escalation. Of the ~$100M rebuild and restart opportunity first flagged in May, management now says $50M to $75M remains available for FY27.

Assessment: A genuine positive, and one that has been consistently under-forecast. The qualification is unchanged from August: a rebuild opportunity and an export constraint can coexist, and the FY27 plan depends on a status-quo assumption about an active conflict. We carry the $50M to $75M as upside rather than in the base, as we did with the original $100M.

Guidance & Outlook

The full FY27 and Q1 framework is tabulated in Key Topic 2 above. What follows is the analytical read on it.

Implied quarter-over-quarter ramp: The Q1 adjusted EPS midpoint of $1.60 represents 9.6% growth on Q1 FY26's $1.46, and the residual $5.65 for Q2 through Q4 represents 10.1% growth on the comparable $5.13. The plan is therefore essentially linear in earnings, which is a change in kind from FY26. Margin is the exception: Q1 at ~28% against a ~29% full year means the remaining three quarters must average roughly 29.3%, and Q4 FY27 would need to exceed the 29.1% just printed. On revenue, ~5% in Q1 against ~5% for the year implies no acceleration is required at all.

Street at: Consensus stood at approximately $7.26 of FY27 adjusted EPS before the print, against the ~$7.25 guided. This is an in-line guide. Post-print sell-side targets moved into roughly the $180 to $200 band, implying 11% to 23% of price appreciation from the current level, so the Street is not disputing the earnings so much as applying a higher multiple to them than we are.

Guidance style: Emerson's recent pattern is to guide conservatively on earnings and to be caught out on cash and on non-operating costs. It beat its own quarterly adjusted EPS guide in each of the last two quarters, by $0.01 above the high end in Q3 and by $0.01 above the point estimate in Q4, and it beat the FY26 adjusted EPS guide set in August by $0.04. Over the same period it missed its own FY26 operating cash flow guide by roughly $122M, its free cash flow guide by roughly $65M, its FY26 GAAP EPS guide by $0.10 and its restructuring add-back guide by 50%. The asymmetry is consistent enough to plan around: treat the adjusted EPS guide as a floor and the GAAP and cash guides as optimistic.

Analyst Q&A Highlights

Why the guide does not match the order book

The opening question went straight to the central tension of the print, and management's first answer was the weaker of the two it would eventually give. The initial response leaned on Europe and China caution. The arithmetic reconciliation, the fall in twelve-month backlog convertibility from 75% to 70%, surfaced later in the call in response to a different line of questioning, and is the better answer.

Q: "I just wanted to stress test the guidance just a little bit. I have to ask. I mean, you had orders up 14%. You got backlog up 11%. Last quarter, orders were up 7%. I can understand the Q1 kind of being relatively conservative on the top line with the 5%. But I would have thought you would have had that accelerating a little bit after Q1."
— Scott Davis, Melius Research

A: "We obviously feel very good about the pacing of orders as we exited them. Really the last 2 quarters and saw significant acceleration in the growth vertical orders, particularly And as Mike pointed out, 37% of sales in Q4 really being driven by projects, whether those are modernizations of greenfield investment So that acceleration gives us significant confidence as we head into the year. And particularly reflected in the backlog growth in the business as well. Having said that, I think your point is valid. We have a Europe that continues to something that we need to watch."
— Surendralal Lanca Karsanbhai, President and Chief Executive Officer

Assessment: The question was right to press, and the conservatism is real but secondary. The primary reason the guide is ~5% is mechanical, and the call eventually supplied it. An investor who stopped at this exchange would conclude the guide is sandbagged. It is not.

Whether the election outcome changes the plan

The most consequential exchange on the call, for reasons that became clear only the following session. The question noted that the prepared remarks were written before the election results were known and asked whether any end market now looked different. Management saw no reason to change the outlook, resting on two years of favourable industrial, energy and near-shoring policy.

Q: "And I have to ask a question. Just I am sure the script is written before the election results. Any tweaks that you would make based on the election results? Or end markets that you might think might be a little better or a little worse?"
— Scott Davis, Melius Research

A: "Not really. I mean, I think we have. I think the industrial policy of The United States, particularly over the last 2 years, has been really positive for our business. Certainly, a. An energy policy, a near shoring policy, has benefited Emerson, and we expect that to continue because, ultimately, those policies do create American jobs and they create American well-being. So we hope that continues. I do not think that would change anything to how we outlook the year right now."
— Surendralal Lanca Karsanbhai, President and Chief Executive Officer

Assessment: A reasonable answer, given before the market repriced the policy risk twenty-four hours later. We do not read this as a management error, because no operating datapoint had changed and the guide was already set. We do read it as confirmation that the FY27 plan contains no handicap for a policy-driven slowdown in data-centre and grid capital formation, which is precisely the exposure that drove the growth verticals to 27% of sales. The honest position is that this is an unpriced two-sided risk, not a known negative.

How far the order book now extends

A follow-up on order duration produced the disclosure that reconciles the whole print. The question asked what proportion of the order book is for fiscal 2028 rather than 2027, reasoning that long-cycle project bookings should be lengthening the book. Management confirmed it directly and supplied the number, together with the offsetting point that short-cycle maintenance demand remains healthy.

Q: "And just a follow-up, just on orders, How should we think about how much of your order book right now is actually for 2028. Versus 2027? Because I do appreciate your comment in China. And Europe, but I would imagine orders reflect those markets as well. So maybe can you talk about from a temporal, like, time perspective, how does it flow? What percent of your order book is for 2027, and how much of it now extends into 2028?"
— Andrew Obin, Bank of America

A: "You will see in the 10-K, you know, we make that disclosure of the percent of the backlog in the next 12 months. And that has been pretty sticky at 75% for a long time. That dropped to 70%. So it is a. Your point is a good 1 and 1 that we have been making as well, that the order book is filling up with long cycle and that is starting to read through. Now that said, MRO activity remains robust in certain markets, and it is exited the year very healthy, high single digits."
— Michael Baughman, Chief Financial Officer

Assessment: The best question of the call, and management answered it fully and against its own short-term interest. A five-point fall in near-term convertibility on an 11% larger backlog means the FY27-shippable order book grew only in the low single digits. This is the datapoint that turns a seemingly cautious guide into a realistic one, and it belongs in any FY27 model built from the order print.

What is different about the first-quarter margin

A question on the implied Q1 incremental margin being below the full-year rate drew a complete itemisation, including a specific cost that reads through a named segment. The answer also produced management's own framing of the FY27 incremental.

Q: "Just on the first quarter, it looks like I think the implied incremental is a little bit lower than what you have guided for the year. I think you have got a bit of an easy software comp. Is there something else in the bridge for the first quarter on margins that we should be aware of?"
— Steve Tusa, Wells Fargo

A: "For the first quarter, we will see year over year improvement. And as you point out, we will get some software contract renewal benefit there. We do have some mix. We are continuing to deliver more projects. We have got some startup cost that is coming in for an expansion that we have done that will affect really the first half and that reads through in intelligent devices. And we continue to invest in the business. As we look at the full year, for the full year, we have dialed in about 80 basis points of improvement, and there will be the software contract dynamic, which creates tailwind And we will continue to do what we have been doing around price-cost being green, and offsetting inflation and cost reduction. So we feel very good about the profitability that we have dialed in the full year incrementals. I think at the midpoint, we are sitting right there at about 40%."
— Michael Baughman, Chief Financial Officer

Assessment: Useful and consistent with our own bridge. Management's "about 40%" incremental sits between the roughly 44% that the reported FY27 margin step implies and the about 37% left after stripping the 35-basis-point renewal tailwind. The first-half start-up cost in Intelligent Devices is a new disclosure and explains why the segment is guided to 3% to 4% in Q1 despite easier comparisons.

Sizing the software renewal tailwind

A two-part question on power order composition and software renewals produced the single most quantitatively useful answer of the call on the margin trajectory. Having sized the drag quarter by quarter, management now put a basis-point figure on the reversal and split it across FY27 and FY28.

Q: "And then on the I wondered if you could give us a sense of how much of the software growth in the quarter was from renewals. And just as we think about that 10% ACV growth next year, where we should be expecting to see sort of lumpiness from those renewals as we look into 2027?"
— Alexander Virgo, Evercore ISI

A: "So on your second 1, Alexander, around software, you know, continue to do very well with our software. And obviously, this year, it was a bit of a headwind with the renewal dynamic costing us 70 basis points. As we have talked about that unwinds roughly half next year, half in 2028. We will get a little more than half next year. So for the year, that should be a tailwind of around 35 basis points."
— Michael Baughman, Chief Financial Officer

Assessment: The disclosure the margin thesis needed, and it cuts against the headline. Forty-four per cent of the guided FY27 expansion, and roughly 35 of the remaining 100 basis points to the 2028 target, is the unwind of a prior-year accounting drag. The target remains reachable. The operating leverage required to reach it is materially less than the trajectory implies, which is a different and less flattering statement than the one the guide makes.

How the test business is planned through the semiconductor cycle

The question pressed on the gap between mid-teens growth just delivered and high single-digit growth guided, against tough comparisons in a book-and-ship business. Management disclosed the phasing and named the assumption it had chosen to make, together with what happens if that assumption proves wrong.

Q: "And then maybe on the organic revenue outlook for Test and Measurement, Just wondered kind of how you have thought about that. You had mid teens growth in Q4. I think you have guided for sort of steady high single digit growth through the next 12 months. I understand it is quite a book and ship business. Comps are tough. So maybe sort of unpack that T and M sales guide a little bit, please."
— Julian Mitchell, JPMorgan

A: "I think at the end of the day, the momentum in T and M, which was about 15% growth in Q4, will certainly continue into the first half. Because we have got visibility, the aerospace and defense segment is very strong. Semis are very strong. And portfolio has moderated. but still high single digits. Obviously, the 1 segment which is now less than $200 million of the portfolio is the automotive piece. Which is the only segment that is slow. Now what we have baked in is a strong first half and then a moderating second half just given a cautious approach to where we see the semi cycle. And the pain of tougher comparisons. I think it is a par plan, how we have laid out. Now, obviously, if the semi business continues to be strong into the second half, then we can certainly do better than the plan we have laid out."
— Ram R. Krishnan, Chief Operating Officer

Assessment: This is how a cyclical business should be guided. The deceleration is a planning choice, it is located in the second half, and the condition that would reverse it is stated. It is also the clearest identified upside in the FY27 plan, and the one most directly exposed to the policy risk that repriced the semiconductor complex the next day. Those two facts are in tension, which is why we neither add the upside nor subtract for the risk in our base estimate.

Why the buyback is front-loaded

A question on repurchase pacing noted that the majority of the full-year program sits in the first quarter and asked whether the driver was cash flow, balance-sheet capacity or the share price. The answer named all three, and conceded the valuation element without hedging.

Q: "And just as a follow-up, I noticed that when I look at the buyback, how front end loaded the buyback is, I think most of it the majority of it is actually in the first quarter relative to the full year guide. Can you just talk about what the driving factor is to front-load it so significantly? Maybe it is just a sort of cash flow thing or balance sheet capacity or maybe a reflection of where you think your stock's trading at? Any color on why it is so front-loaded would be appreciated."
— Amit Mehrotra, UBS

A: "We are committed to the $2.5 billion, but as we have talked about in the sort of longer range capital planning, we do wanna create flexibility for acquisitions. So front loading gave us the opportunity to get the benefit of the lower share count that will, you know, support the 2027 guide. While giving us flexibility as the year unfolds, if an opportunity, a bolt on comes up, we can do that. And still be in a position to deliver 2028. So it was really buying us some flexibility. And, of course, yes, there is a valuation perspective that we took at the time that we saw some opportunity there, and that has certainly borne out over the course of the last couple months."
— Michael Baughman, Chief Financial Officer

Assessment: Candid, and the share-count benefit is already inside the ~$7.25 guide rather than being incremental to it. The sequencing logic is sound: buy early, keep optionality, and if no bolt-on materialises the remaining $1B still gets returned. The mild irony is that a program executed at roughly $139 per share in FY26 is being stepped up 2.5 times at a price 17% higher, which is a less attractive use of the same dollars.

What has to change in China

A question on what could move China in either direction drew the most structurally specific answer management has given on the subject in four quarters, replacing the previous framing of cyclical weakness with a capacity argument.

Q: "And specifically on China, you kind of called it out early as 1 of the reasons for putting out a bigger guide relative to your orders on the top line. What is it that is most concerning to you that could go 1 way or the other in that region? I guess, what do you have your eye on that could change 1 way or the other if the year progresses?"
— Andrew Buscaglia, BNP Paribas

A: "I think as Lal said earlier, we see pockets of growth. I mean, test and measurement business, for example, had 31% growth in China. Now it is $200 million out of the $1 billion we do in China. We see good activity in power, and we see good activity in export business from China. and marine. As those become a larger part of our business, I think you will see some net positive there. But the biggest issue we have is 40% of our sales in China is exposed to petrochemical and refining, and that segment has to new capital formation in a meaningful way, and it is over-capacitized. So until we see that move in a direction of new capacity being added, it is gonna be hard for us to turn China around."
— Ram R. Krishnan, Chief Operating Officer

Assessment: The most valuable thing here is the sizing. China is roughly $1B of sales, about 5% of the company, and 40% of it sits in a market management says is over-capacitised. That bounds the problem: a permanently broken Chinese petrochemical market costs Emerson roughly 2% of revenue, not a growth engine. It also bounds the upside, which is why we do not model a China recovery and treat one as a modest positive rather than a thesis change.

What They're NOT Saying

1. The free cash flow shortfall. FY26 free cash flow finished roughly $65M below the ~$3.6B guided in August and operating cash flow roughly $122M below ~$4.1B. Neither was mentioned in the prepared remarks, and no question in Q&A asked about the shortfall. For a year in which cash was the principal bear point, that silence is notable.
2. What sits in the $245M "Other, net" cash flow swing. This single undisclosed line offset about three-quarters of the $329M increase in the working-capital outflow. Without it, FY26 operating cash flow would have grown 1.6% rather than 8.2%. The release gives no composition.
3. How much IEEPA refund cash was actually collected. The release discloses the $91M annual and $9M quarterly pretax benefit net of a charitable trust contribution, and the $0.12 and $0.01 EPS effects. It does not disclose the cash received in the year, nor the gross refund before the contribution, nor whether further claims remain outstanding.
4. A savings bridge for rising restructuring. FY26 restructuring and related costs reached $227M against $162M, with the EPS add-back at $0.36 against the ~$0.24 guided one quarter earlier. The FY27 guide assumes ~$0.14. No payback analysis has been provided at any point, and Final Control's $93M remains the largest and least explained component.
5. Why the FY27 add-back bridge contains no deal costs or discrete taxes. The guidance table bridges GAAP to adjusted with amortisation and restructuring only. FY26 actually carried $0.14 of acquisition and divestiture fees and $0.05 of discrete taxes. Assuming both go to zero is a choice, not a disclosure.
6. A quantified revenue contribution from AI-enabled products. Repeated quarters of enthusiastic qualitative commentary, now including strong reception for the test assistant and observable migration to the LabVIEW tier containing it, with no revenue figure. The commercial test remains ACV.
7. What happens to the Middle East plan if the conflict escalates. FY27 models high single-digit growth in the region on an explicit status-quo assumption. The downside case for a breach of that assumption has never been sized, in any quarter.

Market Reaction

A timing note, because it changed this quarter: Emerson released before the open on November 4 and held its call at 8:30 a.m. Eastern the same morning. Last quarter it reported after the close. The reaction session is therefore November 4 itself, and the November 5 session that followed is a separate event.

• Pre-print setup: EMR closed November 3 at $166.39, up 25.4% year to date against the S&P 500's 10.6%, up 20.8% over twelve months and up 2.5% over the trailing thirty days. The 52-week closing range entering the print was $123.30 to $170.74.
• Reaction session, November 4: Opened at $166.29, a 0.1% gap down, traded between $163.23 and $172.00, and closed at $170.44, up $4.05 or 2.4%. That is $0.30 below the 52-week closing high.
• Participation: 4.7M shares against a 2.8M thirty-day average, or 1.7 times normal.
• Benchmark: The S&P 500 rose 1.6% on the same session, so the company-specific excess was roughly 0.8 points.
• Follow-through session, November 5: EMR closed at $162.61, down 4.6% on 5.8M shares, two times average. The S&P 500 fell 4.4% the same session and the Nasdaq 100 fell 6.4%.

The reaction-day move is best read as a modest, order-driven endorsement rather than a re-rating. A 2.4% gain on a session when the index rose 1.6% leaves under a point of company-specific response to a quarter that beat every operating target management had set. That is consistent with a market that had already positioned for a good print, which the 25.4% year-to-date advance into the quarter supports, and with a guide that merely met consensus.

The following session requires care, because the headline number invites the wrong conclusion. EMR's 4.6% decline came on a day the S&P 500 fell 4.4% in its worst session since April 2025, driven by a broad repricing of the artificial-intelligence complex on concern about restrictions on data-centre construction. Emerson's excess move was roughly negative 0.2 points. This was not a delayed rejection of the earnings. Across the two sessions together, EMR went from $166.39 to $162.61, a 2.3% decline, against a 2.9% compounded decline in the index, so the stock modestly outperformed while finishing below its pre-print level.

What the second session does change is the context for the thesis rather than the reading of the print. Emerson's growth verticals are 27% of sales, guided to low double-digit growth, and concentrated in exactly the power-generation, grid and semiconductor capital formation the market spent that session repricing. The stock's own resilience relative to the chip complex suggests investors still regard Emerson as a diversified industrial rather than an AI derivative. We agree with that distinction, and note that it holds only while 63% of sales remain maintenance and replacement work.

Street Perspective

Debate: Does a 14% order print justify paying up for FY28?

Bull view: The order book, the $13B funnel and the lengthening backlog give Emerson visibility a conventional short-cycle industrial cannot offer, and the 2028 framework of $21B of revenue, a 30% margin and $8.00 of adjusted EPS is now one year closer with every milestone intact. On that 2028 figure the stock trades near 20 times.

Bear view: The same backlog disclosure that proves duration also shows that near-term convertibility fell five points, so the order print does not translate into revenue any faster. Paying a premium for 2028 earnings requires underwriting two more years of an industrial capex cycle that has just been reminded it is policy-dependent.

Our take: The bulls are right about the business and are stretching on the horizon. We will value FY27 earnings at a premium multiple because the visibility is real, and we will not discount a 2028 target back as though it were contracted. The Street's $180 to $200 target band is an FY28 valuation wearing a twelve-month label.

Debate: Is the margin trajectory operating leverage or accounting?

Bull view: Q4 printed 29.1%, full-year incrementals landed exactly on the 40% framework, price-cost stayed positive through a tariff year, and the FY27 guide of 29% keeps the 2028 target of 30% on a straight line. Four consecutive quarters have beaten the margin plan.

Bear view: Management has now disclosed that 35 of the 80 basis points guided for FY27 is the software renewal unwind, with a similar amount available in 2028. The best segment's 610-basis-point expansion included five points of price, recovered leakage and the easiest comparison of the year. Strip the mechanical items and the operating incremental is below framework.

Our take: Both are describing the same arithmetic and reaching different conclusions, and the bears have the better of it on quality while the bulls have the better of it on outcome. The target will likely be met. It will be met with roughly 40% less operating leverage than the headline trajectory implies, which is a reason to hold our incremental assumption, measured excluding the renewal reversal, at 38% rather than at the realised 51%, not a reason to doubt the number.

Debate: Does the cash miss matter at this size?

Bull view: A $65M shortfall on $3.5B is 1.8%, free cash flow still grew 9% and the margin still expanded 61 basis points, and the FY27 guide takes it to $3.8B to $3.9B. The company funded $2.24B of capital return and cut net debt by $1.20B in the same year. This is noise.

Bear view: Cash has been the weakest element of the story in three of the four FY26 quarters, the shortfall was not addressed on the call, and $245M of the $302M operating cash flow increase came from a favourable swing in an undisclosed line. The FY27 free cash flow guide implies a 19.1% to 19.6% margin against the 20% the 2028 plan requires.

Our take: The size is immaterial and the pattern is not. We have applied a discount to this company's cash guidance in each of the last three reports. Our February range contained the outcome, our May range sat slightly below it, and our August estimate was within $15M. We apply a modest discount again. The more useful observation is that cash is the only leg of the 2028 framework not running ahead of schedule, which makes the first half of FY27 the test rather than a formality.

Our Estimates & Valuation

The FY27 earnings bridge

Our $7.30 estimate starts from the reported FY26 adjusted EPS of $6.59 and accepts the company's revenue and margin framework, then checks it from the bottom up. Revenue of ~$19.93B at a 29% adjusted segment EBITA margin gives $5,780M of segment profit. Deducting adjusted stock compensation of roughly $222M, adding adjusted pension income of roughly $125M and deducting the ~$195M of adjusted corporate and other that management bridged to on the call gives consolidated adjusted EBITA of about $5,488M. That construction reproduces FY26 exactly: $5,360M less $222M plus $125M less $209M equals the $5,054M of adjusted EBITA the release reports.

The company's ~$7.25 guide sits at the bottom of this range, consistent either with a higher assumed tax rate or with deliberate conservatism. We adopt $7.30, which assumes the buyback is executed but not fully reflected in the average share count. A one-point change in revenue growth moves EPS by roughly $0.10 at a 38% incremental; a 50-basis-point change in the segment margin moves it by about $0.14.

Where the 2028 framework stands after one more year

Management reiterated that FY27 delivers results "right in line" with the 2028 targets set at its November 2025 investor conference. The arithmetic largely supports that, with one exception.

A consistent twelve-month valuation

We value FY27 adjusted EPS of $7.30 at 23 to 24 times, producing $167.90 to $175.20, rounded to a $168 to $175 fair-value range for November 2027. The 23.5-times central case is $171.55. The multiple is unchanged from August, and that is a deliberate choice rather than an omission. Two developments argue for a higher multiple: ACV cleared the 10% threshold that had been outstanding for three quarters, and the AspenTech integration closed two years early. Two argue against: the fall in near-term backlog convertibility tempers the visibility premium, and the policy risk to data-centre and grid capital formation is new and unhandicapped. We judge them to offset.

Cross-checking against the later year gives the same answer, which is reassuring. By November 2027 the market will be valuing FY28. Our ~$7.95 FY28 estimate at 21 to 22 times gives $167 to $175, the same range from a different direction.

At the $162.61 close on November 5, EMR trades at 24.7 times FY26 adjusted EPS, 22.3 times our FY27 estimate and 22.4 times the company's guide. On GAAP the multiples are 33.9 times FY26 and 28.5 times the ~$5.70 FY27 guide, a reminder that $1.80 of FY26 add-backs is 27% of adjusted earnings. The new $0.595 quarterly dividend annualises to $2.38, a 1.46% yield, and the FY27 free cash flow guide of $3.85B at the midpoint is a 4.2% yield on the roughly $91.0B market capitalisation, essentially all of which is committed to the ~$3.8B capital-return plan.

The downside case is specific to this quarter's new risk rather than a generic de-rating. If policy restricts data-centre construction, the growth verticals move from low double-digit growth toward flat, removing roughly 2.7 points of company revenue growth. At a 40% incremental that costs about $0.30 of EPS, taking the estimate to $7.00, and a growth-vertical disappointment would compress the multiple toward 20 times. The upside requires the semiconductor cycle to hold through the second half that management has deliberately moderated, Europe or China to contribute rather than merely stop subtracting, and the cash guide to be met rather than missed. These are sensitivities, not equally weighted forecasts.

Thesis Scorecard Post-Earnings

Overall: The thesis is stronger on execution and more complicated on risk. Three of the four bull pillars are confirmed on better evidence than any prior quarter, the software target that had been outstanding since February is met, and two of the three standing bear points move from Emerging to Contained. Against that, the two residual problems are both quality rather than level: cash conversion missed again and is the only leg of the 2028 framework not running ahead, and the margin path depends more on renewal accounting than the trajectory suggests. The newly established policy risk replaces the retiring ones, so the net count of live concerns is unchanged even as the company's delivery improved.

Action: Maintain Hold, conviction 6 of 10, with twelve-month fair value of $168 to $175 and a central value of $171.55. Our FY27 estimate rises to ~$7.30 and our fair value rises with it, but the shares have moved too. At $162.61 the central expected total return of about 7% sits inside our 6% to 8% working assumption for the market, which is the definition of in line rather than ahead. An upgrade requires one of three things: a lower entry price, a first half of FY27 that converts cash at the guided rate and clears the 20% free cash flow margin path, or evidence that the growth verticals can hold low double-digit growth with the policy question resolved. A downgrade would follow a material cut to the growth-vertical outlook, a miss of the FY27 free cash flow guide of $3.8B to $3.9B, or a further upward revision to the restructuring add-back that reveals the ~$0.14 FY27 assumption as understated.